Health
AstraZeneca reports positive trial results for novel COPD biologic treatment
ABC News reports that late-stage trials showed tozorakimab reduced severe COPD exacerbations and gained FDA priority review.
The short version
- AstraZeneca announced late-stage trial data showing its experimental biologic drug tozorakimab reduced moderate and severe COPD exacerbations by up to 34% compared to a placebo.[ABC News]
- The therapy could help individuals managing COPD, a condition that the CDC notes affects nearly 16 million American adults.[ABC News]
- The FDA has granted priority review to the drug as an add-on maintenance therapy, according to AstraZeneca.[ABC News]
- Full findings were shared at a medical congress and remain pending publication in a peer-reviewed journal.[ABC News]
Key facts
- Late-stage clinical trial findings indicate tozorakimab reduced COPD exacerbations by 29% to 34% in former smokers and 29% to 30% in a combined group of current and former smokers.[ABC News]
- The Food and Drug Administration accepted tozorakimab for priority review as an add-on maintenance treatment for adults with COPD, according to AstraZeneca.[ABC News]
- AstraZeneca reported that the drug was well-tolerated with no major side effects beyond reactions at the injection site.[ABC News]
- COPD impacts nearly 16 million U.S. adults and ranks among the top 10 leading causes of death nationwide, according to CDC data.[ABC News]
What remains uncertain
- The clinical trial results have been presented at a conference but have not yet completed publication in a peer-reviewed journal.[ABC News]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.
- New drug shows promise in reducing COPD symptoms in smokers, clinical trials showABC News - Top Stories